TriSalus Life Sciences, Inc.
TLSINASDAQHealthcare● Active
$3.21
+$0.04(+1.26%)
Market Cap$121691610
P/E Ratio—
52W High$7.95
52W Low$2.2
TriSalus Life Sciences, Inc. (TLSI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TLSI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.33
Est. -$0.16 · -106.3%
Revenue
$0.01B
Est. $0.01B · -12.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
TLSI reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.11 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.16 | -$0.33 | -106.3% | $0.01B | $0.01B | -12.7% |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.13 | -$0.12 | +7.7% | $0.01B | $0.01B | +3.0% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.17 | -$0.96 | -464.7% | $0.01B | $0.01B | -12.4% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.22 | -$0.27 | -22.7% | $0.01B | $0.01B | -3.8% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.20 | -$0.33 | -65.0% | $0.01B | $0.01B | +0.8% |
| — Q1 FY2025 | Mar 27, 2025 | -$0.35 | -$0.35 | +0.0% | $0.01B | $0.01B | +1.8% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.36 | -$0.40 | -11.1% | $0.01B | $0.01B | -0.4% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.33
EPS Est.
-$0.16
EPS Surpr.
-106.3%
Revenue
$0.01B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.12
EPS Est.
-$0.13
EPS Surpr.
+7.7%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.96
EPS Est.
-$0.17
EPS Surpr.
-464.7%
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.27
EPS Est.
-$0.22
EPS Surpr.
-22.7%
Revenue
$0.01B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.33
EPS Est.
-$0.20
EPS Surpr.
-65.0%
Revenue
$0.01B
Q1 FY2025
Mar 27, 2025
EPS Actual
-$0.35
EPS Est.
-$0.35
EPS Surpr.
+0.0%
Revenue
$0.01B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.40
EPS Est.
-$0.36
EPS Surpr.
-11.1%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-0.03 | $-0.03 | $-0.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -106.3% | $4.54 | $4.56 | +0.44% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +7.7% | $5.00 | $4.77 | -4.60% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -464.7% | $4.42 | $4.39 | -0.68% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -22.7% | $3.57 | $3.65 | +2.24% |
| ▼ Q2 FY2025 | May 15, 2025 | -65.0% | $4.90 | $5.11 | +4.29% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +0.0% | $5.58 | $5.50 | -1.43% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -11.1% | $4.50 | $4.01 | -10.89% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +57.1% | $5.75 | $5.85 | +1.74% |
Q2 FY2026+0.44%
Report Date
May 12, 2026
EPS Beat/Miss
-106.3%
Price Before
$4.54
Price After
$4.56
Q1 FY2026-4.60%
Report Date
Mar 5, 2026
EPS Beat/Miss
+7.7%
Price Before
$5.00
Price After
$4.77
Q4 FY2025-0.68%
Report Date
Nov 13, 2025
EPS Beat/Miss
-464.7%
Price Before
$4.42
Price After
$4.39
Q3 FY2025+2.24%
Report Date
Aug 12, 2025
EPS Beat/Miss
-22.7%
Price Before
$3.57
Price After
$3.65
Q2 FY2025+4.29%
Report Date
May 15, 2025
EPS Beat/Miss
-65.0%
Price Before
$4.90
Price After
$5.11
Q1 FY2025-1.43%
Report Date
Mar 27, 2025
EPS Beat/Miss
+0.0%
Price Before
$5.58
Price After
$5.50
Q4 FY2024-10.89%
Report Date
Nov 14, 2024
EPS Beat/Miss
-11.1%
Price Before
$4.50
Price After
$4.01
Q3 FY2024+1.74%
Report Date
Aug 14, 2024
EPS Beat/Miss
+57.1%
Price Before
$5.75
Price After
$5.85
Avg Beat Reaction-1.43%
Avg Miss Reaction-0.92%
Beat Rate3 / 8 quarters
Largest Move-10.89% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TLSI ends December
TriSalus Life Sciences, Inc. (TLSI) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.33 — missing the analyst consensus of $-0.16 by -106.3%. The next TLSI earnings date is expected around September 1, 2026.
Each quarter, investors track TLSI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TLSI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TLSI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TLSI earnings · 5 questionsTriSalus Life Sciences, Inc.'s next earnings report is expected around September 1, 2026. TLSI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TLSI historically reports after market close (AMC).
TLSI earnings datewhen is TLSI earningsTLSI next earnings datewhen does TLSI report earningsTLSI earnings calendar
▸ Source: FMP · TriSalus Life Sciences, Inc. SEC filings · US GAAP · TriSalus Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026